Short interest for Premier gives investors a sense of the degree to which investors are betting on the decline of Premier's stock. Short interest data is updated every two weeks.

Premier Stock (NASDAQ:PINC), Short Interest Report

Premier

Premier Inc is a Charlotte, North Carolina-based national group purchasing organization providing primary supply chain services to large hospital systems and more recently to alternate outpatient locations as it expands its footprint. Through acquisitions, the company also offers a compliment of advisory services and consulting services along with software-as-a-service-based subscriptions. The company's revenue is all sourced domestically and is reported in two business segments: the core supply chain services (approximately 70% of fiscal 2019 revenue) and the consulting and technology platform of performance services (approximately 30%).

Ardelyx ARDX

Large Cap

News

Health Care

Legal

General

PINC

FTC probes chemotherapy shortages, scrutinizing drug distributors and hospital groups. Root causes of drug shortages under scrutiny. Industry defends practices.

US Federal Trade Commission Investigates Drug Shortages Amid Allegations Of Market Manipulation

premier Health-Wikimedia Commons

Earnings

Guidance

Buybacks

Movers

Trading Ideas

Premier charts a strategic path with a $1.0 billion share repurchase plan through June 2025. Q2 2024 earnings: EPS $0.60, sales $334.75 million

Healthcare Purchasing Network Premier Launches $1B Share Buyback Program, Concludes Strategic Review Process After Q2 Performance

Dividends

Price Target

Markets

Analyst Ratings

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a  high dividend payout. 

Wall Street&#39;s Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields

Premier Inc

<a href="https://premierinc.com/newsroom/press-releases/premier-inc-announces-strategic-supply-chain-partnership-with-beebe-healthcare">https://premierinc.com/newsroom/press-releases/premier-inc-announces-strategic-supply-chain-partnership-with-beebe-healthcare</a>
&nbsp;

Beebe Healthcare Selects Premier As Supply Chain Operations Strategic Partner

<a href="https://premierinc.com/newsroom/press-releases/clinical-research-collaboration-between-premier-inc-s-pinc-ai-applied-sciences-and-mclaren-health-care-aims-to-advance-patient-outcomes">https://premierinc.com/newsroom/press-releases/clinical-research-collaboration-between-premier-inc-s-pinc-ai-applied-sciences-and-mclaren-health-care-aims-to-advance-patient-outcomes</a>
&nbsp;

'Clinical Research Collaboration Between Premier, Inc.'s PINC AI Applied Sciences And McLaren Health Care Aims To Advance Patient Outcomes' - Premier

Leerink Partners analyst Michael Cherny initiates coverage on Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Market Perform rating and announces Price Target of $22.5.

Initiation

Leerink Partners Initiates Coverage On Premier with Market Perform Rating, Announces Price Target of $22.5

The Federal Trade Commission (FTC) is reportedly launching an investigation into recent shortages of chemotherapies, including carboplatin, cisplatin, and other drugs, aiming to understand the market dynamics contributing to the scarcity of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/06/32816376/drug-shortages-in-focus-how-fdas-quest-for-new-methotrexate-suppliers-affects-the-cancer-treatmen" rel="noreferrer noopener">crucial medicines in U.S. hospitals</a>.&nbsp;
The FTC seeks insights into the practices of drug distributors and hospital purchasing groups, including contracting methodologies, market concentration, and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/22/10/29248173/fda-signals-shortage-for-teva-pharmas-adhd-drug-due-to-manufacturing-delay" rel="noreferrer noopener">compensation structures</a>.&nbsp;
The agency is interested in exploring whether intermediaries facilitating drug purchases for hospitals and those involved in shipping medicines have potentially wielded their market influence to drive down the prices of generic drugs.&nbsp;
The FTC&#8217;s inquiry targets a market dominated by a select few companies. Three key groups handle drug purchases for most U.S. hospitals, while three leading wholesalers supply approximately 90% of drugs to various&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36594393/fda-allows-importing-unapproved-but-essential-syphilis-treatment-amid-shortage-of-pfizers-antibio" rel="noreferrer noopener">healthcare entities nationwide</a>.
The three leading group purchasing organizations (GPO),&nbsp;Vizient,&nbsp;Premier Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>), and&nbsp;HealthTrust&nbsp;represent many hospitals, leveraging their negotiating power to secure low prices.&nbsp;
Critics argue that these prices are so low that some drugmakers reduce production or exit the market altogether.
Cencora Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) (formerly AmerisourceBergen),&nbsp;Cardinal Health Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), and&nbsp;McKesson Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) are the big drug wholesalers.
The agency&#8217;s objective is to examine the root causes of drug shortages, the Wall Street Journal&nbsp;<a target="_blank" href="https://www.wsj.com/health/healthcare/drug-shortages-trigger-ftc-probe-136eca5a?mod=latest_headlines" rel="noreferrer noopener">noted</a>, with an official announcement of the inquiry expected on Wednesday.
Trade associations representing hospital purchasing groups and pharmaceutical distributors have defended their practices amidst the FTC&#8217;s investigation.&nbsp;
The Healthcare Supply Chain Association attributes drug shortages to manufacturers&#8217; quality issues and emphasizes collaborative efforts with hospitals to manage and mitigate shortages.
Similarly, the Healthcare Distribution Alliance, representing pharmaceutical distributors, cites various factors contributing to shortages, such as difficulties in sourcing raw materials and sudden spikes in demand.&nbsp;
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image by HeungSoon from Pixabay

<ul>
<li>Builds on existing partnership by further leveraging the combined power of real-world data, real-world evidence and privacy-preserving record linkage technology to help solve key clinical trial challenges.</li>
<li>Aims to increase trial participant diversity, improve study design and operations, and advance patient experience and outcomes – while saving time and money.</li>
</ul>
PINC AI&#x2122; Applied Sciences (PAS), a division of Premier, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>), and Datavant, the company that protects, connects and delivers the world's health data, announce the companies are expanding their existing collaboration to help shape the future of healthcare research, advance clinical trial operations, and increase trial diversity and equity – aiming to accelerate the development of novel therapies and products for improved patient outcomes.
The organizations have been working together since September 2022 to <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpremierinc.com%2Fnewsroom%2Fpress-releases%2Fdatavant-partners-with-premiers-pinc-ai-applied-sciences-division-to-deliver-meaningful-insights-to-improve-quality-of-care&amp;esheet=53895406&amp;newsitemid=20240213685159&amp;lan=en-US&amp;anchor=compliantly+link+real-world+data&amp;index=1&amp;md5=278332526aa323f3126433cee371fb25">compliantly link real-world data</a> to deliver meaningful insights that improve the quality of patient care. Through this new and expanded effort, PAS will leverage Datavant's trial tokenization solution and data connectivity platform to link clinical trial data and PAS real-world data and generate real-world evidence that propels clinical research innovation. This will provide deeper insights into the benefits and risks of medical interventions in real-world settings within and beyond the controlled environments of clinical trials.
Robust real-world evidence is becoming increasingly important for pharma and medical device development. As an example, with the passage of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.irs.gov%2Finflation-reduction-act-of-2022&amp;esheet=53895406&amp;newsitemid=20240213685159&amp;lan=en-US&amp;anchor=Inflation+Reduction+Act&amp;index=2&amp;md5=afd4fc267872dfab446c959cddce4dee">Inflation Reduction Act</a> (IRA) in August 2022, real-world evidence is serving as an important tool for life sciences and medical device companies striving to demonstrate the value and comparative effectiveness of their products and help patients get access to the therapies and interventions they need faster.
"As life sciences and medical device companies continue to bridge the gap between medical solutions development and real-world application, leveraging real-world data for real-world evidence generation has emerged as a game changer," said Myla Maloney, Chief Growth Officer, PINC AI&#x2122; Applied Sciences. "With Datavant, we are taking our best-in-class, real-world PINC AI&#x2122; Healthcare Data (PHD), securely linking it with other real-world datasets via tokens and leveraging it specifically in the clinical trials space to enable evidence-based decision making, which we believe can lead to better patient experiences and outcomes and cost and time savings."
Today, a clinical trial for a chronic condition is utilizing Datavant to link clinical trial patient data and PHD data to understand the participants' complete patient journey. By uniting clinical trial data with real-world data contained in the PHD, researchers are gaining insight into medication history, which can be difficult to collect, as well as the ability to follow the patients forward after the trial has ended, when oftentimes patients are lost. The real-world evidence generated from the linked data can be used to assess important long-term health outcomes outside of the clinical trial, improve drug safety and efficacy, and empower the healthcare industry to treat chronic care conditions more effectively.
In another clinical trial, a sponsor is building a real-world evidence control arm using PAS' real-world data connected by Datavant at the patient level while preserving patient privacy. Utilizing real-world data/real-world evidence derived from patients on a standard of care may eliminate the need for researchers to construct a separate control arm, which can decrease the duration and cost of the clinical trial. The real-world evidence control arm is also helping to improve the patient experience and outcomes by enabling all study participants to partake in the treatment and its potential benefits rather than a placebo, thereby increasing their access to medical care.
In addition to these active trials, PAS' linkable datasets are being utilized by life sciences and medical device companies and health systems to find diverse trial candidates and identify trial sites – both of which have a critical impact on bringing new solutions to market.
"Ever since launching our trial tokenization offering in 2019, Datavant has held that linking clinical trial data and real-world data has incredible promise to accelerate drug development, improve the safety and efficacy of treatments, and lead to better patient outcomes," said Tal Rosenberg, President and GM, Life Sciences, Ecosystem and Public Sector at Datavant. "We've now tokenized over 100 clinical trials, and we're excited to broaden our work with PAS and accelerate innovation with connected data."

Biotech

Premier, Inc.'s PINC AI Applied Sciences And Datavant Collaborate To Enable Next-Generation Clinical Trials

On Monday,&nbsp;Premier Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) announced it had concluded its exploration of strategic alternatives, and the board has approved a new $1.0 billion&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/b36942012/premier-inc-completes-strategic-review-process" rel="noreferrer noopener">share repurchase authorization</a>.
Repurchases may occur from time to time through June 30, 2025. Under the share repurchase authorization, the company has entered into an accelerated share repurchase agreement with Bank of America to repurchase an aggregate of $400 million.
As part of its review process, the company seeks partners for some or all of Premier&#8217;s holdings in Contigo Health, a subsidiary focused on providing comprehensive services that optimize employee health benefits, and S2S Global, a direct sourcing subsidiary.
&#8220;After a thorough review of alternatives, we are excited to move forward with a more focused strategy predicated on automating and streamlining all aspects of the supply chain and leveraging our unique data, technologies, and AI capabilities to support provider performance improvement and growth in certain adjacent markets,&#8221; said Michael J. Alkire, Premier&#8217;s President and CEO.&nbsp;
Earnings:&nbsp;Premier reported second quarter 2024 adjusted EPS of $0.60, down 14% Y/Y, beating the consensus of $0.57
The company reported sales of $334.75 million, down 7% Y/Y, better than the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/b36942009/premier-inc-reports-fiscal-year-2024-second-quarter-results" rel="noreferrer noopener">consensus estimate of $341.50</a>.
Revenues declined from the prior year primarily due to a challenging revenue comparison for enterprise license agreements in the Performance Services segment, the impact of higher aggregate member fee share in the group purchasing business, and continued market conditions in the direct sourcing business.
Guidance:&nbsp;Premier expects fiscal year 2024 adjusted EPS of $2.06-$2.18 compared to&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $2.16</a>.
The company sees 2024 revenue of $1.265 billion-$1.325 billion compared to the consensus of $1.33 billion.
The guidance includes Supply Chain Services revenues of $840 million-$880 million and Performance Services segment sales of $425 million-$445 million.
Price Action: PINC shares are up 6.32% at $22.28 on the last check Tuesday.
Photo via Wikimedia Commons

Premier Shares Halted On Circuit Breaker To The Downside, Stock Now Up 3.10%

WIIM

Premier Inc shares are trading higher after the company authorized a $1 billion buyback and said it will seek partners to take ownership in some or all of its holdings in Contigo Health and S2S Global. The company also reported Q2 earnings results.

Premier Sees FY24 Adj. EPS $2.06-$2.18 Vs $2.16 Est.; Revenue $1.265B-$1.325B Vs $1.331B Est.

Premier Inc Board Concludes Strategic Review Process; Board Authorizes $1B Buyback And Says It Will  Seek Partners To Take Ownership Of Some Or All Of Its Holdings In Contigo Health And S2S Global

Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.57 by 5.26 percent. The company reported quarterly sales of $334.75 million which missed the analyst consensus estimate of $341.50 million by 1.98 percent. This is a 6.92 percent decrease over sales of $359.63 million the same period last year.

Earnings Beats

Earnings Misses

Premier Q2 2024 Adj EPS $0.60 Beats $0.57 Estimate, Sales $334.75M Miss $341.50M Estimate

Real-world data to support early patient identification for patients with neurodegenerative and behavioral health diseases.
NEW YORK, Jan. 24, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4072353-1&amp;h=3340054075&amp;u=https%3A%2F%2Fwww.langaware.com%2F&amp;a=LANGaware">LANGaware</a>, an innovative leader in digital cognitive and behavioral health diagnostics, is announcing that it will partner with Premier's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) PINC AI&#x2122; Applied Sciences (PAS) to leverage Real-World Data (RWD) for the development of novel therapeutics addressing neurodegenerative and behavioral health diseases.
PAS, renowned for its robust data gleaned from over 4,350 hospitals and 300,000 continuum-of-care providers nationwide, will provide expertise in conducting prospective research utilizing retrospective synthetic arms built from the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4072353-1&amp;h=3169349542&amp;u=https%3A%2F%2Fcdn.sanity.io%2Ffiles%2Fdcd4gsuh%2Fproduction%2F2b237b0c01176d2b17f6291773b8ff790f3e2f74.pdf&amp;a=PINC+AI%E2%84%A2+Healthcare+Database">PINC AI&#x2122; Healthcare Database</a> (PHD).&nbsp;
"Neurodegenerative diseases like Alzheimer's and Parkinson's and behavioral health conditions such as depression affect millions of people worldwide," said Denise Juliano, Group Vice President of Life Sciences at PINC AI&#x2122; Applied Sciences. "The PAS-LANGaware partnership will enable RWD that supports early patient identification and detection – and drives evidence-based decisions by clinicians to improve quality, lower costs, reduce risk and help ensure safety for these patients."
LANGaware, known for its AI-driven precision in early detection, aims to extend the availability of its platform to individuals, health systems and life science companies. Through unique voice and language biomarkers, LANGaware's technology reduces the likelihood of false positives and unnecessary treatments.
"We are thrilled to partner with PAS and extend the reach of our digital assessment tool to more patients, health systems and life science companies," said Vassiliki Rentoumi, Founder and CEO of LANGaware. "Our goal is to revolutionize early detection of cognitive and mental health diseases, supporting novel therapy development as well as earlier intervention by providers, to improve patient outcomes and drive positive changes in the healthcare industry. We are actively seeking partners that share our commitment to transforming patient care."
The collaboration signifies a significant step forward in expanding access to advanced diagnostic services across the United States. By combining PAS' extensive network of health systems and PINC AI's RWD capabilities with LANGaware's cutting-edge technology, the partnership aims to revolutionize healthcare by driving innovation in early detection and treatment.

LANGaware Forges Transformative Collaboration With Premier, Inc.'s PINC AI Applied Sciences To Revolutionize Healthcare

Leveraging comprehensive real-world data (RWD) and AI-enabled tools from PAS, TFS will gain enhanced capabilities to assess site suitability on a larger scale and focus on appropriate patient populations, investigator availability, therapeutic areas expertise and historical clinical trial performance metrics. This data-driven approach has already enabled PAS-supported trials to improve recruitment by 1800 percent and triple enrollment compared to baseline projections – significantly reducing enrollment periods and costs.

Premier's PINC AI Applied Sciences And TFS HealthScience To Partner To Improve Patient Outcomes And Reduce Health Disparities; Combine TFS' Capabilities, Systems And Clinical Development Expertise With PAS' AI-Enabled Technology And Healthcare Database

Teleflex Was Awarded The Peripheral Access Purchasing Agreement With Premier Effective December 1st, 2023

TRVN

Trevena Has Been Awarded A National Group Purchasing Agreement For Olinvyk With Premier Effective December 1, 2023, The New Agreement Allows Premier Members, To Take Advantage Of Special Pricing And Terms Pre-negotiated By Premier For Olinvyk

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a <a href="https://www.benzinga.com/yield-investments"> high dividend payout. </a>
Benzinga readers can review the latest analyst takes on&nbsp;their favorite stocks&nbsp;by visiting our&nbsp;<a href="https://www.benzinga.com/analyst-stock-ratings" target="_blank">Analyst Stock Ratings&nbsp;</a>page. Traders can sort through Benzinga&#39;s extensive database of analyst ratings, including&nbsp;by analyst accuracy. Here&#39;s a look at the most recent high-yield dividend&nbsp;stock ratings from the most accurate Wall Street analysts, according to Benzinga&#39;s&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock&nbsp;</a><a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Ratings</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3>Pfizer Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>)</h3>
<ul>
<li>Dividend Yield: 5.38%</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $39 to $37 on Nov. 1, 2023. This analyst has an accuracy rate of 66%.</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and cut the price target from $39 to $35 on Oct. 17, 2023. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: Astellas Pharma and Pfizer announced FDA approval of supplemental marketing application for Xtandi (Enzalutamide) for nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.</li>
</ul>
<h3>Bristol-Myers Squibb Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bmy#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.58%</li>
<li>BMO Capital analyst Evan Seigerman downgraded the stock from Outperform to Market Perform with a price target of $60. This analysts has an accuracy rate of 61%.</li>
<li>HSBC analyst Rajesh Kumar upgraded the stock from Reduce to Hold and lowered the price target from $55 to $53 on Oct. 27, 2023.This analyst has an accuracy rate of 61%.</li>
<li>Recent News: The FDA approved Bristol Myers Squibb&rsquo;s Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).</li>
</ul>
<h3>Premier, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pinc#NASDAQ">PINC</a>)</h3>
<ul>
<li>Dividend Yield: 4.02%</li>
<li>JP Morgan analyst Anne Samuel maintained a Neutral rating and cut the price target from $26 to $21 on Nov. 13, 2023. This analyst has an accuracy rate of 63%.</li>
<li>UBS analyst Kevin Caliendo maintained a Neutral rating and cut the price target from $29 to $26 on Aug. 23, 2023. This analyst has an accuracy rate of 78%.</li>
<li>Recent News: Premier posted upbeat earnings for the first quarter.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/11/35938765/over-1m-bet-on-heartland-express-check-out-these-4-stocks-insiders-are-buying"> Over $1M Bet On Heartland Express? Check Out These 4 Stocks Insiders Are Buying </a>

Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields

<ul>
<li>Extends group purchasing organization (GPO) contract for 10 years.</li>
<li>Expands services to include co-management of supply chain operations, automation technologies and consulting for financial performance improvement.</li>
</ul>
Premier, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>), a leading technology-enabled performance improvement company, today announced a renewed partnership with Tufts Medicine, a leading integrated health system bringing together the best of academic and community medicine to deliver exceptional, connected and accessible care experiences to consumers across Massachusetts and beyond.
Tufts Medicine and Premier are undertaking a 10-year strategic partnership to expand and extend their shared supply chain goals and capabilities. As part of this relationship, Tufts Medicine will leverage Premier's Nexera supply chain consulting arm to co-manage the people, processes and technologies needed to drive efficiency and total cost management.
"Premier is an ideal strategic partner in the market for supply chain services, and we believe they are uniquely positioned to manage our operations and employees with the winning combination of market leading, price-competitive contracts, automation technologies and data-driven insights," said Susan Green, Chief Financial Officer at Tufts Medicine. "Together with Premier, we will drive operational excellence across our integrated health system, enabling us to stay relentlessly focused on achieving our vision to create the most equitable and frictionless healthcare experience in the world."
Beyond Nexera's supply chain management services, Tufts Medicine will have expanded access to <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pinc-ai.com%2F&amp;esheet=53831236&amp;newsitemid=20231115928369&amp;lan=en-US&amp;anchor=PINC+AI&amp;index=1&amp;md5=26aaa7ef0e54f6557dae6872ef9a07cc">PINC AI</a>&#x2122; performance improvement technologies to aggregate and standardize systemwide spend and utilization data, as well as <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnam10.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.premierinc.com%252Fremitra%26data%3D04%257C01%257CMaria_English%2540PremierInc.com%257Cf73d10631ad14ee35c3e08d984518170%257Cb110eddf23ae457ca6f3734d592b2847%257C0%257C0%257C637686307861050807%257CUnknown%257CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%257C1000%26sdata%3D2P7RE1te4wASZ8oSa0p5Z%252BJtvy%252FBgdO%252FYsm2Rw0CtyE%253D%26reserved%3D0&amp;esheet=53831236&amp;newsitemid=20231115928369&amp;lan=en-US&amp;anchor=Remitra&amp;index=2&amp;md5=8f5fc4510e029f2b35c2b9330765475d">Remitra</a>&#xAE;, Premier's procure-to-pay (P2P) platform that seamlessly automates manual payment and invoicing processes to reduce waste and save time for both healthcare providers and suppliers. In addition, Tufts Medicine will leverage PINC AI&#x2122; consulting services to pinpoint cost savings opportunities and accelerate supply chain innovation across the organization.
"Tufts Medicine joins hundreds of other large, integrated health systems that rely on Premier for our differentiated ability to achieve superior savings, performance excellence and resiliency for the future," said Andy Brailo, Chief Commercial Officer of Premier. "Premier prides itself on our ability to co-innovate with members and this partnership speaks volumes of the confidence we've built and the real-world results we can deliver."
The financial terms of the partnership were not disclosed.

Contracts

Tufts Medicine Selects Premier, Inc. As Strategic Partner To Achieve Supply Chain Excellence; The Financial Terms Of The Partnership Were Not Disclosed

JP Morgan has decided to maintain its Neutral rating of Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) and lower its price target from $26.00 to $21.00.
Shares of Premier are trading up 0.0% over the last 24 hours, at $19.20 per share.
A move to $21.00 would account for a 9.38% increase from the current share price.
<h3>About Premier</h3>
Premier Inc is a Charlotte, North Carolina-based national group purchasing organization providing primary supply chain services to large hospital systems and more recently to alternate outpatient locations as it expands its footprint. Through acquisitions, the company also offers a compliment of advisory services and consulting services along with software-as-a-service-based subscriptions. The company's revenue is all sourced domestically and is reported in two business segments: the core supply chain services (approximately 70% of fiscal 2019 revenue) and the consulting and technology platform of performance services (approximately 30%).
<h3>About Analyst Ratings</h3>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JP Morgan Maintains Neutral Rating for Premier: Here's What You Need To Know

JP Morgan analyst Anne Samuel maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Neutral and lowers the price target from $26 to $21.

JP Morgan Maintains Neutral on Premier, Lowers Price Target to $21

Analysts have provided the following ratings for Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) within the last quarter: 
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
According to 8 analyst offering 12-month price targets in the last 3 months, Premier has an average price target of $27.25 with a high of $32.00 and a low of $24.00. 
Below is a summary of how these 8 analysts rated Premier over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
<img src="https://www.benzinga.com/files/images/story/2023/1699563615_0.png" alt="price target chart" />
This current average has decreased by 20.44% from the previous average price target of $34.25. 
<a href="https://www.benzinga.com/quote/PINC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Premier analyst ratings.</a>
<h1>How Are Analyst Ratings Determined?</h1>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings for Premier

Premier Inc (PINC) has released an update to notify the public and investors about a regulation fd disclosure. The Company recently discussed its h...

Premier Inc Ends Review and Launches $1B Stock Buyback

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Premier (PINC – Research Report) and AstraZeneca (...

Analysts Offer Insights on Healthcare Companies: Premier (PINC) and AstraZeneca (GB:AZN)

Jim Kelly, an analyst from Leerink Partners, has initiated a new Hold rating on Premier (PINC). Jim Kelly has given his Hold rating due to a combin...

Premier's Hold Rating: Balancing Medical Supply Chain Dominance with Growth Uncertainties and GPO Headwinds

The pharmaceutical industry is rapidly expanding, fueled by continued R&D efforts leading to the discovery of new drugs and therapies, biotechnology innovations, and growing medical needs. Thus, let's take a look at pharma gems Pacira BioSciences (PCRX), Calliditas Therapeutics (CALT), and Astellas Pharma (ALPMY) poised for breakthroughs. Read more… The pharmaceutical market is experiencing steady growth, driven by increasing demand for innovative treatments amid an aging population and rising prevalence of rare and chronic diseases. Continued research and development (R&amp;D) innovation resulting in the discovery and development of new drugs and treatment options would boost the industry's prospects.
Considering these factors, investors could consider buying top pharmaceutical stocks Pacira BioSciences, Inc. (<a href="https://stocknews.com/stock/PCRX/">PCRX</a>), Calliditas Therapeutics AB (publ) (<a href="https://stocknews.com/stock/CALT/">CALT</a>), and Astellas Pharma Inc. (<a href="https://stocknews.com/stock/ALPMY/">ALPMY</a>) poised for significant growth.
The global pharmaceutical market is projected to reach $1.16 trillion this year, with oncology drugs segment leading at $214.10 billion. By 2028, the global pharma market is expected to grow at a CAGR of 6.2%, reaching $1.47 trillion. The United States is also anticipated to lead globally, <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">generating the highest revenue of $636.90 billion</a> in 2024.
Besides, driven by rising chronic diseases, a rapidly aging population, and the availability &amp; utilization of innovative therapeutics in developed markets, IQVIA reported an increase in <a href="https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-2024-outlook-to-2028">global medicine use by 12%</a>, with an annual use projected at 3.80 trillion defined daily doses. Spending on medicine is forecasted to grow by 38% through 2028.
As a result, global spending on medicines is projected to reach <a href="https://www.iqvia.com/newsroom/2024/01/global-medicine-spending">$2.30 trillion by 2028</a>. This represents a significant growth trajectory, with spending expected to exceed pre-pandemic levels and biotechnology accounting for 39% of global spending, reaching over $892 billion by 2028.
Furthermore, the biopharma industry is booming due to the growing demand for personalized medicines and several advancements in biotechnology, including biologics, gene editing, cell therapy, and the integration of bioinformatics and data analytics into drug discovery and development processes.
The global biopharma market is estimated at $516.79 billion in 2024 and is expected to grow at a CAGR of 8.1% to reach<a href="https://www.mordorintelligence.com/industry-reports/global-biopharmaceuticals-market-industry"> $761.80 billion by 2029.</a>
Considering these conducive trends, let's examine the fundamentals of three <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> stock picks, beginning with the third choice.
Stock #3: Pacira BioSciences, Inc. (<a href="https://stocknews.com/stock/PCRX/">PCRX</a>)
PCRX focuses on developing and marketing non-opioid pain management and regenerative health solutions for healthcare professionals in the United States. Its products include EXPAREL, ZILRETTA, and the iovera system, offering innovative alternatives to traditional opioid-based treatments.
On March 13, 2024, PCRX announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201, a gene therapy for osteoarthritis of the knee. Preliminary clinical findings suggest potential as a disease-modifying therapy, with well-tolerated and promising efficacy observed in a Phase 1 trial.
On February 7, PCRX announced that it had secured a national group purchasing agreement for EXPAREL with Premier, Inc. (<a href="https://stocknews.com/stock/PINC/">PINC</a>), effective January 1, 2024, enabling Premier members to access special pricing for the non-opioid pain management solution.
This collaboration aims to enhance patient care, reduce opioid reliance, and optimize cost savings for healthcare organizations.
PCRX's total revenues increased 5.4% year-over-year to $181.24 million in the fourth quarter that ended December 31, 2023. The company's non-GAAP net income and net income per common share grew 22% and 21.9% from a year-ago quarter to $45.11 million and $0.89, respectively. Moreover, its <a href="https://www.investopedia.com/terms/a/adjusted-ebitda.asp">adjusted EBITDA</a> rose 11.3% from the prior-year quarter to $65.39 million.
The company forecasts total revenue to be between $680 million and $705 million for the fiscal year 2024, alongside a projected non-GAAP gross margin of 74% to 76%.
Analysts predict PCRX's revenue and EPS will grow by 3.7% and 27.8% year-over-year to $166.30 million and $0.68, respectively, for the fiscal first quarter ending March 2024. Also, the company surpassed consensus revenue estimates in three of the trailing four quarters, which is promising.
PCRX's shares surged by 1.9% intraday to close the last trading session at $30.02.
PCRX's <a href="https://stocknews.com/powr-ratings/">POWR</a><a href="https://stocknews.com/powr-ratings/"> Ratings</a> reflect this promising outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted optimally.
The stock has an A grade for Growth and Value and a B for Quality. In the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry, PCRX is ranked #25 among 165 stocks.
To access additional ratings for PCRX's Momentum, Stability, and Sentiment, <a href="https://stocknews.com/stock/PCRX/">click here</a>.
Stock #2: Calliditas Therapeutics AB (publ) (<a href="https://stocknews.com/stock/CALT/">CALT</a>)
Based in Stockholm, Sweden, CALT specializes in developing and commercializing pharmaceutical products for orphan indications, focusing on renal and hepatic diseases. Its portfolio includes Nefecon for immunoglobulin A nephropathy and Setanaxib, a NOX inhibitor undergoing clinical trials for various conditions.
On March 11, 2024, CALT announced that the FDA had granted an additional seven-year orphan drug exclusivity period for Nefecon&#xAE;, expiring in December 2030. This exclusivity reflects the drug's new indication to reduce kidney function loss in adults with primary immunoglobulin A nephropathy (IgAN), demonstrating significant benefits for patients at risk of disease progression.
On March 6, CALT announced that it had secured seven-year orphan drug exclusivity for TARPEYO&#xAE; until December 2030, following FDA approval for its new indication in reducing kidney function loss in adults with primary immunoglobulin A nephropathy (IgAN).
In the fourth quarter, which ended December 31, 2023, CALT's net sales grew 5.2% from the prior-year quarter to SEK451.56 million ($43.23 million). Its gross and net income increased 1.9% and 28.5% year-over-year to SEK429.26 million ($41.10 million) and SEK41.77 million ($4 million), respectively.
For the fiscal year ending December 2024, Street anticipates CALT's revenue to increase 70.6% year-over-year to $198.53 million, and the company is estimated to report an EPS of $0.11 for the same period. CALT's revenue and EPS for the fiscal year 2025 are expected to grow 62.8% and 1,993.6% year-over-year to $323.12 million and $2.30, respectively.
CALT's stock has gained 30% over the past six months to close the last trading session at $21.30.
CALT's POWR Ratings reflect its robust prospects. The stock has an overall B rating, translating to a Buy in our proprietary rating system.
The stock has a B grade for Value and Sentiment. CALT is ranked #22 within the same industry.
<a href="https://stocknews.com/stock/CALT/">Click here</a> to view CALT's ratings for Growth, Momentum, Stability, and Quality.
Stock #1: Astellas Pharma Inc. (<a href="https://stocknews.com/stock/ALPMY/">ALPMY</a>)
Headquartered in Tokyo, Japan, ALPMY is a leading global pharmaceutical company specializing in treatments for prostate cancer, acute myeloid leukemia, and other medical conditions.
On February 16, ALPMY and Kelonia Therapeutics joined forces to develop Immuno-Oncology therapies, leveraging Kelonia's iGPS&#xAE; and Xyphos' ACCEL&#x2122; technology. Xyphos leads development, offering upfront payments, potential milestones nearing $800 million, and royalties for Kelonia.
During the nine months that ended December 31, 2023, ALPMY's revenue grew 2.1% year-over-year to ¥1.19 trillion ($7.85 billion). Its gross profit increased 3.4% from a year-ago period to ¥969.81 billion ($6.40 billion). The company's operating profit and EPS came in at ¥74.12 billion ($489.46 million) and ¥27.96, respectively.
Analysts expect ALPMY's revenue for the fiscal year ending March 2024 to increase 129.2% year-over-year to $10.50 billion. Its EPS for the ongoing year is expected to be $0.24. Further, the company has surpassed consensus revenue estimates in three of the trailing four quarters.
In addition, for the fiscal year 2025, ALPMY's revenue and EPS are estimated to grow 6.8% and 79.9% from the prior year to $11.21 billion and $0.43, respectively.
The stock has increased marginally intraday to close the last trading session at $10.95.
ALPMY's sound fundamentals are reflected in its POWR Ratings. It has an overall rating of B, equating to a Buy in our proprietary rating system.
It has an A grade for Stability and a B for Value and Quality. ALPMY is ranked #19 in the same industry.
One can see the additional ratings for ALMPY for Growth, Momentum, and Sentiment <a href="https://stocknews.com/stock/ALPMY/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ALPMY shares were trading at $11.07 per share on Thursday morning, up $0.12 (+1.13%). Year-to-date, ALPMY has declined -6.97%, versus a 10.46% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Kritika Sarmah</h2> <img src='https:/wp-content/uploads/2022/08/Kritika-Sarmah_Image-3.jpg' style="float:left; padding:5px;width:125px;">Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist. She earned her bachelor's degree in commerce and is currently pursuing the CFA program. With her fundamental approach, she aims to help investors identify untapped investment opportunities.<a href="https://stocknews.com/authors/?author=kritika-sarmah">More...</a>The post <a href=https://stocknews.com/news/alpmy-pcrx-calt-pinc-3-pharma-gems-poised-for-breakthroughs/>3 Pharma Gems Poised for Breakthroughs</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Pharma Gems Poised for Breakthroughs

Ford, Envista Holdings, and Alaska Air are among additions to GS' Long Duration list

Ford, Envista Holdings, and Alaska Air are among additions to GS' Short Duration list

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Johnson & Johnson (JNJ – Research Report), Axsome Therapeutics (A...

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Axsome Therapeutics (AXSM) and Premier (PINC)

An update from Premier Inc (PINC) is now available. Premier, Inc. is poised to settle a shareholder derivative lawsuit with a $71 million payment t...

Premier Inc to Settle Shareholder Lawsuit with $71M Payment

Barclays analyst Stephanie Davis maintained a Hold rating on Premier (PINC – Research Report) today and set a price target of $24.00. The company's...

Premier (PINC) Receives a Hold from Barclays

Premier declares $0.21 dividend

ALPMY

AXSM

CALT

CNHI

COHR

CRUS

FOXA

FYBR

INTC

LFUS

MRVI

NVST

PARA

PCRX

PRGO

QDEL

RPRX

SWKS

TWLO

VSAT

VTRS

Press Releases

LANGaware Forges Transformative Collaboration with Premier, Inc.'s PINC AI™ Applied Sciences (PAS) to Revolutionize Healthcare

Premier, Inc. Declares Quarterly Cash Dividend

Premier, Inc. Reports Fiscal-Year 2024 Second-Quarter Results

Premier, Inc. Completes Strategic Review Process

Premier, Inc.'s PINC AI™ Applied Sciences and Datavant Collaborate to Enable Next-Generation Clinical Trials

PINC AI™ and Fortune Name the Nation's 50 Top Cardiovascular Hospitals™

Premier, Inc. to Participate in Barclays Global Healthcare Conference on March 12, 2024

Premier, Inc. to Report Fiscal 2024 Third-Quarter Results and Host Conference Call on May 7, 2024

Premier's PINC AI™ and Fortune Name the Nation's 100 Top Hospitals®

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Agiliti

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Premier Stock (NASDAQ:PINC), Short Interest Report

People Also Watch